ACECLOFENAC 100MG + PARACETAMOL 325MG + TRYPSIN-CHYMOTRYPSIN 50000 AU TABLETS are a multiple-component pharmaceutical formulation that combine the following: Aceclofenac, Paracetamol, and Trypsin-Chymotrypsin as an enzyme. The development of this type of formulation requires appropriate development planning to overcome the development challenges posed by combining both ordinary small-molecule pharmaceutical active substances with enzyme components.
Formulation development will include controlling the strength of both Aceclofenac and Paracetamol, while the activity of Trypsin-Chymotrypsin at 50000 AU must also be controlled. The finished product therefore includes naturally bulked enzyme activity which will influence how development is managed, whilst the formulation of both the ingredient and enzyme components will be a key consideration.
The use of conventional pharmaceutical excipients in the finished tablet is likely to include diluents, disintegrants, glidants, lubricants, binders, stabilisers and other formulation aids, as necessary. Selection and proportion of these will be targeted toward achieving the desired finished tablet properties.
The formulation development will take account of moisture, temperature, processing stress, and the interaction of excipients when combined with enzymes, to help preserve the enzyme activity. Control of the finished product will also focus on ensuring the common equipment used in preparation and compression does not adversely impact product stability or performance.
There are three main active component groups in this formulation: Aceclofenac, Paracetamol, and Trypsin-Chymotrypsin. Each will be designed to be precisely dosed when measuring in finished product manufacturing.
Both pharmaceutical powders will be dispensed in accordance with their individual specifications, but the enzyme material of Trypsin and Chymotrypsin may not be pure in terms of physical content but rather as an activity unit measure. This activity level which is expressed as 50000 AU will need to be established in the raw material and monitored during formulation development to understand if any lot-to-lot variation exists.
The other considerations for the enzyme components include the particle size distribution, flow characteristics, stability, and compatibility with other ingredients in the blend. It may be advantageous to consider premixing or diluting the enzyme material in order to ensure a uniform distribution.
Key to enzyme stability throughout manufacturing will be considering the effect of processing stress and selecting appropriate formulation conditions for these enzyme components as part of the development process. The activity levels will be ascertained during testing using validated analytical methods.
The raw materials will be received, sampled, tested, and approved prior to use. When released for use, each raw material will be accurately weighed following the master manufacturing formula and dosage specifications.
Prior to blending, the ingredients may be passed through controlled sieves or other particle-size-adjusting techniques. The components will then be carefully blended in a sequence that facilitates the uniform distribution of both pharmaceutical and enzyme components, allowing time for the enzymes to be thoroughly dispersed throughout the blend.
Batch mixing will be followed by compression with development of parameters relating to machine speed, force of compression, tablet weight, hardness, and thickness. The compression process will need to consider the enzyme activity and the setting of compression conditions that avoid degradation of the enzyme active component.
Finished tablets will be prepared with a suitable set of controls relating to weight, visual appearance, shape, thickness, surface finish, and friability, amongst others. These controls will contribute toward batch uniformity on an ongoing basis.
Quality control testing will focus on the assessment of the individual ingredients in the tablet. The tests will be used to determine the ingredients meet their individual standards and the finished product conforms with its own specifications.
Testing on the finished product will include identification of both the pharmaceutical constituents, as well as the enzyme activities in the preparation, and the relevant tests on other ingredients such as assay, uniformity, dissolution, disintegration, and average weight.
The enzyme component will require validation of the activity unit measure against the enzyme content through appropriate analytical procedures. Content uniformity and assay will need to address the whole finished tablet to ensure the manufacturing process does not impair finished product quality.
Other quality requirements relevant to the formulation include raw material qualification, environment monitoring, change management, deviation management, batch release testing, and manufacturing documentation, all of which will contribute toward consistent batch quality.
The stability of the enzyme materials is likely to be a consideration in the product development lifecycle. Additional studies to ascertain the stability of the enzyme component in the finished tablet at the appropriate temperature and humidity range will be required, and the packaging based on this information.
Environmental factors that have been considered in the development process will feed into a formal stability study. This will monitor changes in physical appearance, assay, enzyme activity, degradation-related parameters, dissolved content, moisture, and other quality measures at regular periods.
Packaging choices for stabilizing the enzyme preparation within the finished product will be selected based on the stability characteristics of the product, the moisture content of the finished tablet, and ease of use in the manufacturer's process.
A suitable barrier type of packaging may include blister packs or strips with the relevant sealing and labeling aspects monitored for each batch. The packaging study may allow for determining the product expiry date, to help support the product's quality in the marketplace.
This specific combination of active ingredients and enzymes within a tablet product format allows a pharmaceutical business the opportunity to develop a wider and more varied pharmaceutical portfolio. Enzymes are specific and need targeted handling in development but can add value to a product portfolio.
The process of developing such combination products involves close collaboration in production, quality assurance, manufacturing, and regulatory departments to ensure that consistency is achieved with regard to both enzyme and pharma content.
The management of raw materials, blending, manufacturing, and packaging processes, along with the development of analytical tests to verify the enzyme activity unit content is critical to product quality. Businesses entering a PCD Pharma Franchise portfolio may consider this as a tablet candidate to support their choice of product lines.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech